abs303.txt	objective		this	study	sought	to	define	the	role	of	first-line	platinum-baseddoublet	chemotherapy	in	older	patients	with	non-small	cell	lung	cancer	(nsclc)	materials	and	methods	we	analyzed	three	nsclc	trials	calgb	9730	30203	30801	which	tested	carboplatin	paclitaxel	gemcitabine	either	pemetrexed	orgemcitabine	respectively	overall	survival	was	primary	endpoint	age-basedcomparisons	a	cutpoint	65	years	were	performed	cox	proportionalhazards	models	adjustments	for	sex	tumor	histology	stage	smoking	history	after	stratifying	by	performance	score	secondary	endpoints	grade	3-5	adverse	events	cycles	completed	whether	toxicity	prompted	discontinuation	results	730	included	337	(46%)	65+	age	nostatistically	significant	difference	observed	(≥65)versus	younger	(hr	=	1	096	95%	ci	(0	94	28)	p	0	25)	trendemerged	increased	odds	event	≥65	yearsversus	<65	(or	52	99	2	31)	05)	proportion	ofcompleted	marginally	lower	patients(difference	-5%	(-9	2)	06)	those	versus<65	but	no	statistically	occurred	rate	ofchemotherapy	4	85	19)	21)	versus	70	yieldedsimilar	conclusion	these	findings	support	doublet-based	inselect	advanced
